Provided by Tiger Fintech (Singapore) Pte. Ltd.

MediWound

16.27
-0.7800-4.57%
Post-market: 16.270.00000.00%16:13 EDT
Volume:239.47K
Turnover:3.92M
Market Cap:175.55M
PE:-5.55
High:16.86
Open:16.86
Low:16.22
Close:17.05
Loading ...

Company Profile

Company Name:
MediWound
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
- -
Office Location:
42 Hayarkon Street,Yavne,Israel
Zip Code:
8122745
Fax:
972 7 797 14111
Introduction:
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Directors

Name
Position
Stefan T. Wills
Active Chairman of the Board, Director
Assaf Segal
Director
Nissim Mashiach
Director
Ofer Gonen
Director
Sharon Kochan
Director
Vickie R. Driver
Director

Shareholders

Name
Position
Sharon Malka
Chief Executive Officer
Boaz Gur Lavie
Chief Financial Officer
Ety Klinger
Chief Research and Development Officer
Lior Rosenberg
Chief Medical Technology Officer
Yaron Meyer
Executive Vice President, General Counsel and Corporate Secretary